- Lilly to buy startup Ajax in bid for a better JAK drug<p>Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.</p>BioPharma Dive · 3mo ago↗ source
- Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder<p>The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor de…BioPharma Dive · 3mo ago↗ source
- Sanofi MS drug rejected in US gets an endorsement in Europe<figure><div><img src="https://imgproxy.divecdn.com/FBR1IQNmU9Hqatva496Zg2G8JMHsqV0UGsf4LMARqYo/g:nowe:189:144/c:1776:1003/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS80OTY5MDc4Mzc…